SCHEMBL2200710

SCHEMBL2200710

Cc1c(C(=O)N2CCCN(CCO)CC2)nn(C)c1-c1cccc(-c2cc3ccccc3o2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 2/20 0.43
HSD17B10 Q99714 3/20 0.39
ALDH1A1 P00352 4/20 0.39
HPGD P15428 4/20 0.39
KDM4E B2RXH2 3/20 0.39
TP53 P04637 1/20 0.39
GAA P10253 1/20 0.39
CASP1 P29466 1/20 0.39
HTT P42858 1/20 0.39
CASP7 P55210 1/20 0.39
DRD2 P14416 2/20 0.38
DRD3 P35462 2/20 0.38
HRH4 Q9H3N8 1/20 0.38
MKNK1 Q9BUB5 4/20 0.38
MKNK2 Q9HBH9 4/20 0.38
EIF4E P06730 1/20 0.38
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37
MEN1 O00255 1/20 0.37
CYP1A2 P05177 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2201254 0.97 ALDH1A1 (0.41) GRIN2BHSD17B10ALDH1A1HPGDKDM4E
SCHEMBL2201671 0.92 DRD3 (0.39) GRIN2BHSD17B10ALDH1A1HPGDKDM4E
SCHEMBL2200712 0.88 GRIN2B (0.44) GRIN2BHSD17B10ALDH1A1HPGDKDM4E
SCHEMBL2202072 0.88 DRD2 (0.46) HSD17B10ALDH1A1HPGDKDM4EDRD2
SCHEMBL2201258 0.85 ALDH1A1 (0.42) GRIN2BHSD17B10ALDH1A1HPGDKDM4E
SCHEMBL2197040 0.83 GRIN2B (0.44) GRIN2BHSD17B10ALDH1A1HPGDKDM4E
SCHEMBL12429330 0.83 GRIN2B (0.44) GRIN2BHSD17B10ALDH1A1HPGDKDM4E
SCHEMBL2201674 0.80 DRD3 (0.40) GRIN2BHSD17B10ALDH1A1HPGDKDM4E
SCHEMBL2197341 0.79 MKNK1 (0.51) ALDH1A1HPGDKDM4EMKNK1MKNK2
SCHEMBL2199009 0.78 GRM5 (0.46) HSD17B10ALDH1A1HPGDKDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
US-7977358-B2 Pyrazol derivatives HOFFMANN-LA ROCHE INC. (US) 2011-07-12 US disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
US-20090029963-A1 PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 US disclosed
WO-2009013211-A2 NEW PYRAZOL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090029963-A1 PYRAZOL DERIVATIVES CCR1, CCR3, CCRL2 GRIN2B 1350/4885HSD17B10 3984/4885ALDH1A1 1476/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.